Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 9/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.70 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.70 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.70 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.70 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.70 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.66 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.66 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626000 | 1.00 | NT5E (0.77) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL625828 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL17211052 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL12932283 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL3502237 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL29471291 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL18269547 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL13857854 | 0.92 | P2RY1 (0.79) | NT5EP2RY1P2RX3P2RY11ENPP1 | |
| SCHEMBL15305345 | 0.91 | NT5E (0.84) | NT5EP2RY1P2RY11P2RY2SRC | |
| SCHEMBL16474336 | 0.91 | NT5E (0.84) | NT5EP2RY1P2RY11P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140371302-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | MODERNATX, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140343129-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY1 2661/4885P2RX3 3314/4885 |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | NT5E 10/4885P2RY1 386/4885P2RX3 736/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | NT5E 10/4885P2RY1 386/4885P2RX3 736/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | NT5E 10/4885P2RY1 386/4885P2RX3 736/4885 |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MMP1, COL2A1, COL1A1 | NT5E 796/4885P2RY1 2616/4885P2RX3 2167/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY1 2929/4885P2RX3 2081/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY1 2929/4885P2RX3 2081/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY1 2661/4885P2RX3 3314/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | NT5E 29/4885P2RY1 825/4885P2RX3 1510/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY1 2661/4885P2RX3 3314/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY1 2929/4885P2RX3 2081/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY1 2929/4885P2RX3 2081/4885 |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | NT5E 648/4885P2RY1 4459/4885P2RX3 3487/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY1 2661/4885P2RX3 3314/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | NT5E 648/4885P2RY1 4459/4885P2RX3 3487/4885 |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | POLRMT, RNMT, RNGTT | NT5E 77/4885P2RY1 2728/4885P2RX3 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.